Healthcare utilization and indirect cost of treatment associated with severe allergic asthma in a real-world setting
Clinical and Translational Allergy volume 3, Article number: P1 (2013)
With an estimated 300 million individuals affected worldwide, asthma is associated with substantial social and economic burden. The cost of treating uncontrolled severe allergic asthma (SAA) is high encompassing a variety of direct medical costs and indirect costs. We present data on real-world healthcare utilization (direct) and school/work absence (indirect) in uncontrolled SAA patients receiving omalizumab in the eXpeRience registry.
eXpeRience was a 2-year, global, single-arm, observational registry. Data were collected on real-world effectiveness, safety and use of omalizumab in patients with uncontrolled SAA. Asthma-related healthcare utilization (hospitalizations, emergency room visits or unscheduled doctor visits) and number of days missed from school/work were recorded.
The intent-to-treat population comprised 916 (97.1%) patients. Compared with the pre-treatment period, there were reductions in healthcare utilization and school/work absence after 12 and 24 months of omalizumab treatment.
About this article
Cite this article
Braunstahl, GJ., Deenstra, M., Canvin, J. et al. Healthcare utilization and indirect cost of treatment associated with severe allergic asthma in a real-world setting. Clin Transl Allergy 3 (Suppl 1), P1 (2013). https://doi.org/10.1186/2045-7022-3-S1-P1
- Emergency Room
- Medical Cost
- Indirect Cost
- Economic Burden
- Healthcare Utilization